EUDA Home
  • EN

General population surveys (GPS)

Statistics found here the category is General population surveys of drug use (GPS) and where the keyword is all adults (15-64)

Category Title
GPS GPS-1. Last 12 months prevalence of cannabis use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for youth (aged 15 to 24)
GPS GPS-2. Continuation rates of cannabis use (last 12 months use and last 30 days use as proportions of lifetime use)
GPS GPS-6. Last 12 months prevalence of amphetamines use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
GPS GPS-7. Last 30 days prevalence of cannabis use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
GPS GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24) Part (i) All age groups
GPS GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24) Part (ii) Males aged 15 to 24 in countries with high prevalence rates
GPS GPS-10. Last 12 months prevalence of cannabis use by age group in United Kingdom (E&W)
GPS GPS-11. Continuation rates of ecstasy use (last 12 months use and last 30 days use as proportions of lifetime use)
GPS GPS-12. Last 12 months prevalence of cannabis use by age group Part (i) Selected EU-15 Member States
GPS GPS-12. Last 12 months prevalence of cannabis use by age group Part (ii) Selected ‘new’ EU Member States
GPS GPS-15. Last 12 months prevalence of cocaine use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
GPS GPS-16. Continuation rates of cocaine use (last 12 months use and last 30 days use as proportions of lifetime use)
GPS GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15–64) and young adults (aged 15–34) Part (i) Cannabis use — lifetime experience, last 12 months and last 30 days prevalence
GPS GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15–64) and young adults (aged 15–34) Part (ii) Cocaine, amphetamines and ecstasy use — lifetime experience, last 12 months and last 30 days prevalence
GPS GPS-22. Continuation rates of amphetamine use (last 12 months use and last 30 days use as proportions of lifetime use)
GPS GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (i) Survey methods
GPS GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (ii) All adults (aged 15–64)
GPS GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (i) All adults (aged 15–64)
GPS GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000 Part (i) All adults (aged 15–64)
GPS GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (i) All adults male (aged 15–64)
GPS GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (ii) All adults female (aged 15–64)
GPS GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (i) All adults male (aged 15–64)
GPS GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (ii) All adults female (aged 15–64)
GPS GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (i) All adults male (aged 15–64)
GPS GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000 Part (ii) All adults female (aged 15–64)
GPS GPS-7. Lifetime prevalence of drug use in all available national general population surveys Part (ii) All adults (aged 15–64)
GPS GPS-8. Last 12 months prevalence of drug use in all available national general population surveys Part (i) All adults (aged 15–64)
GPS GPS-9. Last 30 days prevalence of drug use in all available national general population surveys Part (i) All adults (aged 15–64)
GPS GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys Part (i) All adults (aged 15–64) - most recent data
GPS GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys Part (ii) All adults (aged 15–64) - 2007 field trial
GPS GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys Part (iii) All adults (aged 15–64) - 2004 field trial

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Thursday, 14 July 2011